Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
J Clin Endocrinol Metab. 2013 Jun;98(6):2451-9. doi: 10.1210/jc.2012-3899. Epub 2013 May 23.
Seafood long-chain polyunsaturated omega-3 fatty acids (n-3 PUFAs) improve insulin sensitivity in animal experiments, but findings remain inconsistent in humans. Adiponectin is a robust marker for insulin sensitivity and adipocyte function. Whether n-3 PUFAs affect adiponectin in humans is unknown.
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, the objective of the study was to perform a systematic review and meta-analysis of randomized, placebo-controlled clinical trials (RCTs) to determine the effect of n-3 PUFA consumption on circulating adiponectin in humans.
MEDLINE, EMBASE, CABI (CAB abstracts), Cochrane Central Registry of Controlled Trials, ClinicalTrials.gov, SIGLE, and Faculty of 1000 were searched through to June 2012, supplemented with author contact and reference list searches.
RCTs of either fish oil supplementation or isocaloric fish meal feeding that evaluated adiponectin as an outcome were selected for the study.
Two investigators independently extracted the data. Effect estimates were pooled using inverse-variance weighted, random-effects meta-analysis. Heterogeneity was assessed by the I(2) and Q statistic. Prespecified sources of heterogeneity were investigated by meta-regression. Publication bias was assessed using funnel plots and Egger's test.
Of 110 studies, 14 RCTs met inclusion criteria. Fourteen trial arms evaluated fish oil (fish oil, n = 682; placebo, n = 641). Fish oil increased adiponectin by 0.37 μg/mL [95% confidence interval (CI) 0.07; 0.67, P = .02]. Although effects in 11 of 14 trials were 0 or greater, statistical heterogeneity was evident (I(2) = 72.9%), unexplained by n-3 PUFA dose or duration, study quality score, study location, or baseline body mass index (meta-regression P > .05 each). The funnel plot was asymmetric in favor of smaller trials with greater effects (Egger's P = .11); the fill-and-trim method suggested a theoretical pooled effect of 0.18 μg/mL (95% CI -0.15; +0.52, P = .28). Only 2 trial arms evaluated fish feeding (n = 136 intervention and 68 control subjects), for which the pooled effect on adiponectin was not statistically significant (-0.01 μg/mL, 95% CI -0.65; 0.64, P = 0.99), although CIs were broad due to the small number of subjects.
In placebo-controlled RCTs, fish oil moderately increases circulating adiponectin, although with unexplained heterogeneity as well as potential publication bias. These findings provide no evidence for harm and support possible benefits of n-3 PUFA consumption on insulin sensitivity and adipocyte function.
海鲜长链多不饱和ω-3 脂肪酸(n-3 PUFA)可改善动物实验中的胰岛素敏感性,但在人类中的研究结果仍不一致。脂联素是胰岛素敏感性和脂肪细胞功能的一个强有力的标志物。n-3 PUFA 是否会影响人类的脂联素尚不清楚。
根据系统评价和荟萃分析的首选报告项目指南,本研究的目的是对随机、安慰剂对照临床试验(RCT)进行系统评价和荟萃分析,以确定 n-3 PUFA 摄入对人类循环脂联素的影响。
通过 MEDLINE、EMBASE、CABI(CAB 摘要)、Cochrane 对照试验中心注册库、ClinicalTrials.gov、SIGLE 和 Faculty of 1000 进行了搜索,截至 2012 年 6 月,同时补充了作者联系和参考文献搜索。
选择了评估脂联素为结局的鱼油补充或等热量鱼餐喂养的 RCT 进行研究。
两名调查员独立提取数据。使用逆方差加权、随机效应荟萃分析合并效应估计值。通过 I(2)和 Q 统计量评估异质性。通过荟萃回归调查了预定的异质性来源。使用漏斗图和 Egger 检验评估发表偏倚。
在 110 项研究中,有 14 项 RCT 符合纳入标准。14 个试验组评估了鱼油(鱼油,n = 682;安慰剂,n = 641)。鱼油使脂联素增加了 0.37μg/ml[95%置信区间(CI)0.07;0.67,P =.02]。尽管 14 项试验中的 11 项的效果为 0 或更大,但存在明显的统计学异质性(I(2) = 72.9%),无法用 n-3 PUFA 剂量或持续时间、研究质量评分、研究地点或基线体重指数(荟萃回归 P >.05 各)解释。漏斗图偏向于具有更大效果的较小试验(Egger 的 P =.11);填充和修剪法提示理论上的汇总效应为 0.18μg/ml(95%CI-0.15;+0.52,P =.28)。只有 2 个试验组评估了鱼喂养(n = 136 个干预组和 68 个对照组),其对脂联素的汇总效果无统计学意义(-0.01μg/ml,95%CI-0.65;0.64,P = 0.99),尽管由于研究对象数量较少,CI 较宽。
在安慰剂对照 RCT 中,鱼油可适度增加循环脂联素,但存在未解释的异质性以及潜在的发表偏倚。这些发现没有提供 n-3 PUFA 消费对胰岛素敏感性和脂肪细胞功能有害的证据,并支持 n-3 PUFA 消费可能带来益处。